Innovent Biologics, Inc. (HKG:1801)

Innovent Biologics Revenue

Innovent Biologics had revenue of 8.62B CNY in the half year ending June 30, 2026, with 118.05% growth. This brings the company's total for the last twelve months to 15.71B, up 37.50% year-over-year. In the year 2025, Innovent Biologics had annual revenue of 13.04B with 38.42% growth. That makes Innovent Biologics the 4,564th largest company in the world by revenue and 303rd in Hong Kong.

• Revenue (ttm): 15.71B CNY
• Revenue Growth: +37.50%
• P/S Ratio: 8.48
• Revenue / Employee: 1.79M CNY
• Employees: 8,754
• Market Cap: 151.11B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Geography

Chart

• The People's Republic of China (PRC) 12.07B 92.5%
• Europe 571.81M 4.4%
• United States of America ("USA") 380.61M 2.9%
• Other 19.63M 0.2%

Fiscal year ended Dec 31, 2025 See the full Innovent Biologics breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	13.04B	3.62B	38.42%
Dec 31, 2024	9.42B	3.22B	51.82%
Dec 31, 2023	6.21B	1.65B	36.21%
Dec 31, 2022	4.56B	286.65M	6.71%
Dec 31, 2021	4.27B	425.91M	11.08%

Data Source: S&P Global Market Intelligence Last updated: Sep 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Nov 11, 2026

Data Sources Report a data error